Nivolumab and Eribulin in HER2 Negative Metastatic Breast Cancer
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Nivolumab
Sponsor: Seoul National University Hospital
Collaborators: Seoul National University Bundang Hospital|Korean Cancer Study Group (KCSG)|Eisai Korea Inc.|Ono pharmaceutical Korea